These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 2684528)
1. Hemodynamics in hemodialysis patients treated with recombinant human erythropoietin. Nonnast-Daniel B; Schäffer J; Frei U Contrib Nephrol; 1989; 76():283-9; discussion 290-1. PubMed ID: 2684528 [TBL] [Abstract][Full Text] [Related]
2. Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin. Steffen HM; Brunner R; Müller R; Degenhardt S; Pollok M; Lang R; Baldamus CA Contrib Nephrol; 1989; 76():292-8. PubMed ID: 2582783 [TBL] [Abstract][Full Text] [Related]
3. Hypertension as a possible complication of recombinant human erythropoietin therapy. Brunkhorst R; Nonnast-Daniel B; Koch KM; Frei U Contrib Nephrol; 1991; 88():118-25; discussion 126. PubMed ID: 2040173 [TBL] [Abstract][Full Text] [Related]
4. Adverse cardiovascular effects of partial correction of renal anemia by recombinant human erythropoietin. Frei U; Nonnast-Daniel B; Schäffer J; Koch KM Contrib Nephrol; 1990; 82():72-8. PubMed ID: 2093530 [TBL] [Abstract][Full Text] [Related]
6. Effect of recombinant human erythropoietin treatment on hemodynamic parameters in continuous ambulatory peritoneal dialysis and hemodialysis patients. Fernández A; Vega N; Jiménez F; Macía M; Laraudiogoitía E; Hortal L; Perdomo M; Plaza C; Rodríguez JC; Palop L Am J Nephrol; 1992; 12(4):207-11. PubMed ID: 1481867 [TBL] [Abstract][Full Text] [Related]
7. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Pascual J; Teruel JL; Moya JL; Liaño F; Jiménez-Mena M; Ortuño J Clin Nephrol; 1991 Jun; 35(6):280-7. PubMed ID: 1831414 [TBL] [Abstract][Full Text] [Related]
8. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics. Tagawa H; Nagano M; Saito H; Umezu M; Yamakado M Clin Nephrol; 1991 Jan; 35(1):35-8. PubMed ID: 2007294 [TBL] [Abstract][Full Text] [Related]
9. Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure. Haedersdal C; Mehlsen J; Stenver D; Nielsen B; Jeppesen L; Winther K Angiology; 1994 Mar; 45(3):231-4. PubMed ID: 8129205 [TBL] [Abstract][Full Text] [Related]
10. Blood rheology in hemodialysis patients treated with recombinant human erythropoietin. Brunner R; Pollok M; Heidel M; Müller R; Degenhardt S; Baldamus CA Contrib Nephrol; 1989; 76():306-12; discussion 312-4. PubMed ID: 2582784 [No Abstract] [Full Text] [Related]
11. Hemodynamic changes in hemodialyzed patients during treatment with recombinant human erythropoietin. Teruel JL; Pascual J; Jiménez M; Liaño F; Rivera M; Martínez J; Moya JL; Ortuño J Nephron; 1991; 58(2):135-7. PubMed ID: 1865967 [TBL] [Abstract][Full Text] [Related]
12. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients. Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091 [TBL] [Abstract][Full Text] [Related]
13. Renal anaemia treatment with recombinant human erythropoietin increases cardiac output in patients with ischaemic heart disease. Linde T; Wikström B; Andersson LG; Danielson BG Scand J Urol Nephrol; 1996 Apr; 30(2):115-20. PubMed ID: 8738056 [TBL] [Abstract][Full Text] [Related]
14. Role of blood rheology in the pathogenesis of hypertension of hemodialysis patients treated for renal anemia with recombinant human erythropoietin. Baldamus CA; Steffen AM; Brunner R; Pollok M Contrib Nephrol; 1990; 82():79-85. PubMed ID: 2093531 [No Abstract] [Full Text] [Related]
15. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin. Schwartz AB; Prior JE; Mintz GS; Kim KE; Kahn SB Transplant Proc; 1991 Apr; 23(2):1827-30. PubMed ID: 2053168 [TBL] [Abstract][Full Text] [Related]
16. Effect of hemodialysis and recombinant human erythropoietin on determinants of blood viscosity. Shand BI; Buttimore AL; Lynn KL; Bailey RR; Robson RA Ren Fail; 1994; 16(3):407-13. PubMed ID: 8059023 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis. Yamakado M; Umezu M; Nagano M; Tagawa H Clin Invest Med; 1991 Dec; 14(6):623-9. PubMed ID: 1794212 [TBL] [Abstract][Full Text] [Related]
18. [Erythropoietin--the first hematologic hormone in clinical use]. Rhyner K Schweiz Med Wochenschr; 1988 Mar; 118(11):375-80. PubMed ID: 3287601 [TBL] [Abstract][Full Text] [Related]
19. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. Frank H; Heusser K; Höffken B; Huber P; Schmieder RE; Schobel HP Kidney Int; 2004 Aug; 66(2):832-40. PubMed ID: 15253740 [TBL] [Abstract][Full Text] [Related]
20. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Löw-Friedrich I; Grützmacher P; März W; Bergmann M; Schoeppe W Am J Nephrol; 1991; 11(1):54-60. PubMed ID: 1828650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]